FactSet(FDS) - 2025 Q4 - Earnings Call Presentation
2025-09-18 13:00
Fiscal Year 2025 Key Accomplishments - FactSet achieved over 45 years of consecutive revenue growth[10] - The company saw 29 years of consecutive adjusted diluted EPS growth[10] - There were 26 years of consecutive dividend growth[10] - Organic ASV growth reached $127 million, exceeding the guidance range of $100-$130 million[11] - Annual Revenue was $2,322 million, within the guidance range of $2,305-$2,325 million[12] - Adjusted Operating Margin was 363%, aligning with the guidance range of 360%-370%[13] - Adjusted Diluted EPS was $1698, within the guidance range of $1680-$1740[13] Q4 2025 Financial Performance - Revenues increased by 62% to $596901 thousand[33] - Organic Revenues increased by 45% to $587326 thousand[33] - Adjusted Operating Margin decreased by 200 bps to 338%[19] - Adjusted Diluted EPS increased by 83% year-over-year to $405[19] ASV Growth & Key Metrics - Organic ASV grew by 57%[19] - Total Organic ASV reached $2,371 million[23] - Wealth segment ASV grew by 10% to $371 million[23] - Institutional Buy-Side ASV grew by 4% to $1,156 million[23] - Partnerships & CGS ASV grew by 8% to $401 million[23] - Dealmakers ASV grew by 4% to $443 million[23] - EMEA ASV grew by 4% to $586 million[23] - ASIAPAC ASV grew by 7% to $243 million[23] - AMERICAS ASV grew by 6% to $1,542 million[23] - ASV Retention was >95%[25] - Client Retention was 91%, up approximately 90 bps versus 2024 | Q4[28,30] - User Count increased by 10% to 237,324[27,28] - Client Count increased by 9% to 8,996[29,30] Fiscal Year 2026 Outlook - Organic ASV Growth is projected to be $100 - $150 million (~42% to ~62%)[41] - Revenues are expected to be $2,423 - $2,448 million[41] - GAAP Operating Margin is projected to be 295% - 310%[41] - Adjusted Operating Margin is projected to be 340% - 355%[41] - GAAP Diluted EPS is projected to be $1455 - $1525[41] - Adjusted Diluted EPS is projected to be $1690 - $1760[41]
DuPont (NYSE:DD) 2025 Earnings Call Presentation
2025-09-18 13:00
Investor Day 2025 TM Transform. Innovate. Accelerate. 2025 INVESTOR DAY 1 Welcome and Opening Remarks Ann Giancristoforo Vice President, Investor Relations 2 2 2025 INVESTOR DAY 2025 INVESTOR DAY Forward looking statements On January 15, 2025, DuPont de Nemours, Inc. ("DuPont", or after the completion of the Intended Electronics Separation, "New DuPont") announced it is targeting November 1, 2025 to complete the intended separation of its Electronics business (the "Intended Electronics Separation") by way o ...
Arthur J. Gallagher (NYSE:AJG) Earnings Call Presentation
2025-09-18 13:00
CFO Commentary September 18, 2025 Arthur J. Gallagher & Co. Forward-Looking Statements and Non-GAAP Measures Information Concerning Forward-Looking Statements This CFO Commentary contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this CFO Commentary, the words "anticipates," "believes," "contemplates," "see," "should," "could," "will," "estimates," "expects," "intends," "plans" and variations thereof and similar expressions, are int ...
Radian Group (NYSE:RDN) Earnings Call Presentation
2025-09-18 12:30
Acquisition Overview - Radian 将以 17 亿美元的价格收购 Inigo,资金来自现有流动性和超额资本,无需筹集股权[6] - 预计该交易将在 2026 财年实现两位数(mid-teens)的 GAAP 每股收益增长[6] - 预计该交易将在 2026 财年实现约 200 个基点的 GAAP 股本回报率增长[6] Inigo 的财务表现和特点 - Inigo 是一家领先的 Lloyd's 专业保险公司,预计 2025 年的 GWP(总书面保费)为 16 亿美元[13, 20] - Inigo 自成立以来,总书面保费以每年 39% 的速度增长[15] - Inigo 的多元化投资组合包括 10 多个险种,涵盖财产、意外、金融和其他专业类别[16] - Inigo 的业务主要集中在美国,美国占 GWP 的 70%[19] Radian 的战略调整 - Radian 将专注于抵押贷款保险业务,并剥离所有其他业务[7] - 剥离所有其他业务预计将减少 36% 的费用,并使 Radian 的独立股本回报率提高 120 个基点[12] 市场机遇 - 通过收购 Inigo,Radian 的潜在市场将扩大 12 倍[29]
SEI Investments (NasdaqGS:SEIC) 2025 Earnings Call Presentation
2025-09-18 12:30
This presentation contains forward-looking statements within the meaning or the rules and regulations of the Securities and Exchange Commission. In some cases you can identify forward-looking statements by terminology, such as "may," "will," "expect," "believe," "remain" and "continue" or "appear." Our forward-looking statements include our current expectations as to: You should not place undue reliance on our forward-looking statements, as they are based on the current beliefs and expectations of our manag ...
Darden Restaurants(DRI) - 2026 Q1 - Earnings Call Presentation
2025-09-18 12:30
Earnings Call Fiscal 2026: First Quarter Results September 18, 2025 Disclaimer/Non-GAAP Information IMPORTANT NOTICE The following slides are part of a presentation by Darden Restaurants, Inc. (the "Company") and are intended to be viewed as part of that presentation (the "Presentation"). No representation is made that the Presentation is a complete description of the Company's performance, financial condition or outlook. Forward-looking statements in this communication regarding our expected earnings perfo ...
Nanobiotix (NasdaqGS:NBTX) Earnings Call Presentation
2025-09-18 12:00
Immunorad September 2025 Data on Phase 1 Trial Safety and preliminary efficacy of NBTXR3/SBRT in combination with Immune Checkpoint Inhibitors in anti-PD-1 resistant patients with melanoma treated in the phase I trial Study 1100 Cohort 3 – Melanoma Subgroup Analysis Jason W. Chan, MD, Ari Rosenberg, MD, Alexander Lam, MD, James Lee, MD, Adil Daud, MD, William A. Stokes, MD,Nabil F. Saba, MD, Frances Collichio, MD, Hyeon Yu, MD, Priya Mody, MD, Jared Weiss, MD, Stergios Moschos, MD,Steven Powell, MD, Shannon ...
Super Group (NYSE:SGHC) 2025 Earnings Call Presentation
2025-09-18 12:00
Super Group Overview - Super Group's LTM (Last Twelve Months) revenue is $2.1 billion and LTM Adjusted EBITDA is $486 million[51] - The company paid $166 million in dividends as of Q2 2025[51] - Super Group's sports gross margin was 13.9% in 1H 2025, compared to 11.8% in 1H 2024[30] - The company has approximately 3,000 employees across 16 countries[15] Customer Acquisition and Retention - AI-driven customer service led to a 70% increase in customers serviced, a 45% increase in host productivity, and a 60% decrease in abandon rates[30] - Key customer engagement metrics increased by 25% due to personalized marketing[28] - Bot-assisted advantage betting decreased by approximately $187,000[28] - Approximately 74% of Betway Global's H1 2025 gross revenue came from pre-2025 cohorts[194] - Approximately 80% of SPIN's H1 2025 gross revenue came from pre-2025 cohorts[128] - Approximately 93% of Betway Africa's H1 2025 gross revenue came from pre-2025 cohorts[291] Market Opportunity and Growth - The global interactive Total Addressable Market (TAM) is estimated to be $209 billion in 2025 and $338 billion in 2030, representing a 10% Compound Annual Growth Rate (CAGR)[53] - The iGaming market is projected to reach $142 billion in 2030, with a five-year CAGR of approximately 11% from 2025[120] - Betway Africa's H1 2025 total revenue was over $420 million, a 37% year-over-year increase, representing 40% of Group Net Revenue[239]
Lucid Diagnostics (NasdaqCM:LUCD) Earnings Call Presentation
2025-09-18 11:00
Company Overview - Lucid Diagnostics Inc is a commercial-stage cancer prevention company focused on esophageal precancer screening[4] - The company's mission is to prevent esophageal cancer deaths in at-risk patients through a comprehensive precancer screening solution[6] - Lucid's solution includes EsoCheck for esophageal cell collection and EsoGuard Esophageal DNA Test for detecting epigenetic changes[24, 32] Market Opportunity - The total addressable U S market for EsoGuard is approximately $60 billion, targeting ~30 million at-risk GERD patients recommended for screening[8, 52] - The Medicare payment for EsoGuard is approximately $1,938 per test[52] - The company boasts over 90% gross margin per test[53] Clinical and Financial Performance - EsoGuard has a 96% sensitivity for detecting esophageal cancer and precancer[39] - Since launch, approximately 36,000 cumulative EsoGuard tests have been performed[79] - The company's pro forma cash as of 2Q25, including September CMPO, is $58.1 million[81] Esophageal Cancer Context - Esophageal cancer has a low 5-year survival rate of 13%[14] - The incidence of Esophageal Adenocarcinoma (EAC) has increased by 573% from 1975 to 2020[16] - Approximately 16,250 estimated U S deaths from esophageal cancer in 2025[17]
Daiichi Sankyo (OTCPK:DSKY.F) Earnings Call Presentation
2025-09-17 23:00
WCLC 2025 Highlights DAIICHI SANKYO CO., LTD. September 17th (US)/ 18th (JP), 2025 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are vario ...